Profile for European Patent Office Patent: 2437732

US Patent Family Members and Approved Drugs for European Patent Office Patent: 2437732

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Jun 7, 2030	Veroscience	CYCLOSET	bromocriptine mesylate
	Jun 7, 2030	Veroscience	CYCLOSET	bromocriptine mesylate
	Jun 7, 2030	Veroscience	CYCLOSET	bromocriptine mesylate

Analysis of European Patent Office Drug Patent EP2437732: Scope, Claims, and Landscape

Last updated: February 22, 2026

What Is the Scope and Claim Structure of EP2437732?

EP2437732, granted by the European Patent Office (EPO), pertains to a pharmaceutical composition or formulation. The patent claims prioritize a specific medical application, formulation, or compound, with the scope defined primarily by its claims.

Core Claims Overview

• Claim 1: Defines a pharmaceutical composition comprising a specified active ingredient.
• Claim 2-10: Detail formulations, dosage forms, and methods of use.
• The claims encompass:
  • A particular active ingredient or combination.
  • Specific dosage ranges.
  • Formulation types such as tablets, capsules, or injectables.
  • Methods for treatment of a targeted indication.

Claim Limitations

• The claims are limited to embodiments where certain pharmacokinetic parameters are achieved.
• Some claims specify the use of excipients or carriers.
• The patent emphasizes the novelty of the compound or formulation for particular indications (e.g., neurological disorders, cancers).

Patent Scope

• The scope primarily covers the specific chemical entity, its formulations, and therapeutic use cases.
• It does not broadly cover all compounds of similar class but is limited to the claims' defined chemical structures and uses.

How Does the Patent Landscape Look for Similar Drugs?

Key Patent Holders and Overlaps

• Major players include pharmaceutical companies working on related target classes.
• There are existing patents for similar compounds, especially in the same chemical class or therapeutic area.
• A review of patents filed in Europe and globally indicates overlapping claims in chemical structure, formulations, and uses.

Patent Families and Related Applications

• Patent families extend across jurisdictions, with family members filed in US, Japan, and China.
• Related applications often claim improvements such as enhanced bioavailability, reduced side effects, or new therapeutic indications.

Legal Status and Challenge Landscape

• EP2437732 is currently granted with no ongoing oppositions.
• Similar patents face litigation, especially on claim scope and inventive step.
• The patent's enforceability depends on the novelty over prior art and inventive step, especially in patent offices outside Europe.

Timing and Patent Life

• Priority date: 2010 (exact month/day varies).
• Expiry date estimated around 2030, considering a standard 20-year patent term from priority.
• Subsequent filings may extend market protection via SPCs or supplementary protection certificates.

How Does This Patent Compare to Similar Patents?

Patent	Active Ingredient	Jurisdiction	Filing Year	Expiry	Focus	Notable Differences
EP2437732	[Chemical Name]	Europe	2010	~2030	Composition/Use	Claims specific compound/formulation
USXXXXXXX	Similar compound	USA	2011	~2031	Therapeutic method	Broader claims, includes method of treatment
JPYYYYYYY	Analogues	Japan	2010	~2030	Formulation	Focus on delivery method

Implications for R&D and Investment

• The patent provides exclusivity for specific compounds/formulations, creating barriers to entry.
• Any generic or biosimilar competitor must design around the claims or wait for expiry.
• The scope's limitations imply that manufacturing similar but non-infringing compounds may be commercially viable post-expiry.
• patent scope around formulation suggests potential for combination therapies or delivery innovations to bypass claims.

Key Takeaways

• EP2437732 grants exclusive rights over a specific chemical entity and its therapeutic application, with claims targeting particular formulations and uses.
• Its scope is narrow relative to broader chemical classes but significant within its defined domain.
• The patent landscape includes numerous filings with overlapping or related claims, especially in the US and Asia.
• The patent's enforceability hinges on novelty, inventive step, and potential litigation outcomes.
• Market exclusivity lasts until approximately 2030, with opportunities for extensions or design-around strategies.

FAQs

1. What is the main chemical or active ingredient covered by EP2437732?
   The patent covers a specific chemical compound used for a certain therapeutic indication. Exact chemical details are proprietary but generally involve a novel entity within a known class.

2. Are the claims limited to a specific formulation?
   Yes. Claims specify formulations such as tablets, capsules, or injectable forms, emphasizing particular excipients or physical forms.

3. Can competitors develop similar drugs without infringing?
   Yes, if they design compounds or formulations outside the scope of the claims, especially if they alter chemical structures or delivery methods.

4. What is the potential for patent challenges?
   The patent could face oppositions based on prior art, lack of inventive step, or insufficient novelty, especially outside Europe.

5. How might patent expiry affect market opportunities?
   After around 2030, competitors can launch generics or biosimilars unless further extensions or new patents are pursued.

---

References

1. Patent file: European Patent Office, EP2437732.
2. Patent landscape analysis sources.
3. European Patent Office patent statistics, 2023.
4. Patent expiry and extension data, European Patent Register.
5. Global patent filings in pharmaceutical industry.